PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2023 | 9 | nr 1 | 29--34
Tytuł artykułu

Nephrological complications in patients after COVID-19 infection

Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
In this review, we looked for correlations and health consequences between COVID-19 infection and kidney health. Although the main symptoms of COVID-19 are respiratory failure and hypoxemia, kidney involvement is also common. In an attempt to decipher how COVID-19 infection affects the kidneys, this review focuses on the pathophysiological and clinical links between COVID-19 infection and the kidneys. The aim of this work was to find long-term health consequences in patients who were discharged from the hospital and to investigate risk factors. COVID-19-related kidney disease is reported not only in infected patients with chronic kidney disease, but also in people with no previous history of kidney disease. The disease caused by the coronavirus (COVID-19) is a threat to public health. Chronic kidney disease (CKD) has been shown to be a risk factor for side effects. Although initial reports from China showed a low incidence (5%-10%) of acute kidney injury (AKI), subsequent articles documented a much higher incidence of AKI in hospitalized COVID-19 patients. Overall, renal biopsies showed a variety of histopathology, including acute glomerulonephritis and acute tubular injury. The pathophysiology of COVID-19-associated AKI is believed to include local and systemic inflammatory and immunological reactions, endothelial damage, and activation of coagulation pathways and the renin-angiotensin system. Histopathology results revealed both similarities and differences between AKI in COVID-19 patients and AKI patients in non-COVID-19 sepsis. Acute tubular injury is common, although it is often mild despite greatly reduced kidney function. Systemic haemodynamic instability most likely contributes to renal tubular damage. Despite the description of COVID-19 as a cytokine storm syndrome, circulating cytokine levels are often lower in patients with COVID-19 than in patients with acute respiratory distress syndrome from causes other than COVID-19. Also, an impaired response to type I interferon has been detected in patients with severe COVID-19. In the light of these observations, the potential pathophysiological mechanisms of COVID-19-associated AKI may provide knowledge to construct therapeutic strategies.(original abstract)
Słowa kluczowe
Czasopismo
Rocznik
Tom
9
Numer
Strony
29--34
Opis fizyczny
Twórcy
  • Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ w Lublinie
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
  • Uniwersytet Medyczny w Lublinie
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie
  • 1 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Lublinie
  • Kliniczny Szpital Wojewódzki Nr 1 im. Fryderyka Chopina w Rzeszowie
  • Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego SPZOZ w Lublinie
Bibliografia
  • Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8. PMID: 33428867; PMCID: PMC7833295.
  • Chan L, Hindi J, Nadkarni GN. COVID-19: The Kidneys Tell a Tale. Am J Kidney Dis. 2021 Feb;77(2):175-177. doi: 10.1053/j.ajkd.2020.11.001. Epub 2020 Dec 17. PMID: 33342610; PMCID: PMC7834848.
  • Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, Cantaluppi V. Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol. 2021 Nov;17(11):751-764. doi: 10.1038/s41581-021-00452-0. Epub 2021 Jul 5. PMID: 34226718; PMCID: PMC8256398.
  • Gupta S, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 2021;32:161-176. doi: 10.1681/ASN.2020060897.
  • Cantaluppi V, et al. A call to action to evaluate renal functional reserve in patients with COVID-19. Am. J. Physiol. Renal Physiol. 2020;319:F792-F795. doi: 10.1152/ajprenal.00245.2020.
  • Peng S, et al. Early versus late acute kidney injury among patients with COVID-19 - a multicenter study from Wuhan, China. Nephrol. Dial. Transpl. 2020;35:2095-2102. doi: 10.1093/ndt/gfaa288.
  • Portolés J, et al. Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. Nephrol. Dial. Transpl. 2020;35:1353-1361. doi: 10.1093/ndt/gfaa189.
  • Russo E, et al. Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. J. Nephrol. 2021;34:173-183. doi: 10.1007/s40620-020-00875-1.
  • Cheng Y, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97:829-838. doi: 10.1016/j.kint.2020.03.005.
  • Cummings MJ, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763-1770. doi: 10.1016/S0140-6736(20)31189-2.
  • Gupta S, et al. AKI treated with renal replacement therapy in critically ill patients with COVID-19. J. Am. Soc. Nephrol. 2021;32:161-176. doi: 10.1681/ASN.2020060897.
  • Cantaluppi V, et al. A call to action to evaluate renal functional reserve in patients with COVID-19. Am. J. Physiol. Renal Physiol. 2020;319:F792-F795. doi: 10.1152/ajprenal.00245.2020.
  • Peng S, et al. Early versus late acute kidney injury among patients with COVID-19 - a multicenter study from Wuhan, China. Nephrol. Dial. Transpl. 2020;35:2095-2102. doi: 10.1093/ndt/gfaa288.
  • Chan L, et al. AKI in hospitalized patients with COVID-19. J. Am. Soc. Nephrol. 2021;32:151-160. doi: 10.1681/ASN.2020050615
  • Guan W-J, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708-1720. doi: 10.1056/NEJMoa2002032.
  • Pei G, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J. Am. Soc. Nephrol. 2020;31:1157-1165. doi: 10.1681/ASN.2020030276.
  • Batlle D, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J. Am. Soc. Nephrol. 2020;31:1380-1383. doi: 10.1681/ASN.2020040419.
  • Werion A, et al. SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney Int. 2020;98:1296-1307. doi: 10.1016/j.kint.2020.07.019.
  • Ferlicot S, et al. The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury, and/or proteinuria. Nephrol. Dial. Transplant. 2021 doi: 10.1093/ndt/gfab042.
  • Sharma P, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J. Am. Soc. Nephrol. 2020;31:1948-1958. doi: 10.1681/ASN.2020050699.
  • Golmai P, et al. Histopathologic and ultrastructural findings in postmortem kidney biopsy material in 12 patients with AKI and COVID-19. J. Am. Soc. Nephrol. 2020;31:1944-1947. doi: 10.1681/ASN.2020050683.
  • Sharma P, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J. Am. Soc. Nephrol. 2020;31:1948-1958. doi: 10.1681/ASN.2020050699.
  • Remmelink M, et al. Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit. Care. 2020;24:495. doi: 10.1186/s13054-020-03218-5.
  • Akilesh S, et al. Multicenter clinicopathologic correlation of kidney biopsies performed in COVID-19 patients presenting with acute kidney injury or proteinuria. Am. J. Kidney Dis. 2020;77:82-93.e1. doi: 10.1053/j.ajkd.2020.10.001.
  • Rahmani H, et al. Interferon β-1b in treatment of severe COVID-19: a randomized clinical trial. Int. Immunopharmacol. 2020;88:106903. doi: 10.1016/j.intimp.2020.106903.
  • Davoudi-Monfared E, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob. Agents Chemother. 2020;64:e01061-20. doi: 10.1128/AAC.01061-20.
  • Kudose S, et al. Kidney biopsy findings in patients with COVID-19. J. Am. Soc. Nephrol. 2020;31:1959-1968. doi: 10.1681/ASN.2020060802.
  • Wu H, et al. AKI and collapsing glomerulopathy associated with COVID-19 and APOL1 high-risk genotype. J. Am. Soc. Nephrol. 2020;31:1688-1695. doi: 10.1681/ASN.2020050558.
  • Ferlicot S, et al. The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury, and/or proteinuria. Nephrol. Dial. Transplant. 2021 doi: 10.1093/ndt/gfab042.
  • Sharma P, et al. COVID-19-associated kidney injury: a case series of kidney biopsy findings. J. Am. Soc. Nephrol. 2020;31:1948-1958. doi: 10.1681/ASN.2020050699.
  • Ackermann M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120-128. doi: 10.1056/NEJMoa2015432.
  • Pfister F, et al. Complement activation in kidneys of patients with COVID-19. Front. Immunol. 2020;11:594849. doi: 10.3389/fimmu.2020.594849.
  • Cugno M, et al. Complement activation in patients with COVID-19: a novel therapeutic target. J. Allergy Clin. Immunol. 2020;146:215-217. doi: 10.1016/j.jaci.2020.05.006.
  • Zhang S, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020;13:120. doi: 10.1186/s13045-020-00954-7.
  • Hottz ED, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330-1341. doi: 10.1182/blood.2020007252.
  • Shi H, et al. Endothelial cell-activating antibodies in COVID-19. Preprint at. medRxiv. 2021 doi: 10.1101/2021.01.18.21250041.
  • Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol. Med. 2008;14:502-516. doi: 10.2119/2008-00006.Legrand.
  • Cunha LL, Perazzio SF, Azzi J, Cravedi P, Riella LV. Remodeling of the immune response with aging: immunosenescence and its potential impact on COVID-19 immune response. Front. Immunol. 2020;11:1748. doi: 10.3389/fimmu.2020.01748.
  • Buszko M, et al. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat. Immunol. 2020;21:1146-1151. doi: 10.1038/s41590-020-0779-1.
  • Legrand M, Mik EG, Johannes T, Payen D, Ince C. Renal hypoxia and dysoxia after reperfusion of the ischemic kidney. Mol. Med. 2008;14:502-516. doi: 10.2119/2008-00006.Legrand.
  • Fogagnolo A, et al. Focus on renal blood flow in mechanically ventilated patients with SARS-CoV-2: a prospective pilot study. J. Clin. Monit. Comput. 2021 doi: 10.1007/s10877-020-00633-5.
  • Vasquez-Bonilla WO, et al. A review of the main histopathological findings in coronavirus disease 2019. Hum. Pathol. 2020;105:74-83. doi: 10.1016/j.humpath.2020.07.023.
  • Zoufaly A, et al. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 2020;8:1154-1158. doi: 10.1016/S2213-2600(20)30418-5.
  • Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Neutralizing antibodies for the treatment of COVID-19. Nat. Biomed. Eng. 2020;4:1134-1139. doi: 10.1038/s41551-020-00660-2.
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.ekon-element-000171661890

Zgłoszenie zostało wysłane

Zgłoszenie zostało wysłane

Musisz być zalogowany aby pisać komentarze.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.